86945-25-7

Basic information

• Product Name: 4-(2-Aminoethyl)-1-benzylpiperidine
• Synonyms: RARECHEM AN KA 2335;AKOS BBS-00006795;4-(2-AMINOETHYL)-1-BENZYLPIPERIDINE;2-(1-BENZYL-4-PIPERIDYL)ETHYLAMINE;2-(1-BENZYLPIPERIDIN-4-YL)ETHANAMINE;2-(1-BENZYL-PIPERIDIN-4-YL)-ETHYLAMINE;Aminoethylbenzylpiperidine;2-(1-benzyl-4-piperidinyl)ethanamine(SALTDATA: FREE)
• CAS NO: 86945-25-7
• Molecular Formula: C₁₄H₂₂N₂
• Molecular Weight: 218.34
• Product Categories: Aminomethyl's;Pyrans, Piperidines &Piperazines;Pyrans, Piperidines & Piperazines
• Mol File: 86945-25-7.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 319.4 °C at 760 mmHg
• Flash Point: 136.4 °C
• Appearance: /
• Density: 0,99 g/cm3
• Vapor Pressure: 0.000339mmHg at 25°C
• Refractive Index: 1.5320-1.5350
• PKA: 10.43±0.10(Predicted)
• CAS DataBase Reference: 4-(2-Aminoethyl)-1-benzylpiperidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-Aminoethyl)-1-benzylpiperidine(86945-25-7)
• EPA Substance Registry System: 4-(2-Aminoethyl)-1-benzylpiperidine(86945-25-7)

Safety Data

• Hazard Codes: T,Xi
• Statements: 36/37/38-41-25
• Safety Statements: 26-36/37/39-45-39
• HazardClass: IRRITANT
• Hazardous Substances Data: 86945-25-7(Hazardous Substances Data)

Usage

General Description

4-(2-Aminoethyl)-1-benzylpiperidine is a chemical compound with a molecular formula C16H24N2. It belongs to the piperidine class of compounds and contains an amine functional group. 4-(2-Aminoethyl)-1-benzylpiperidine has potential pharmacological properties and may have applications in the field of medicine. It is known for its psychoactive effects and has been studied for its potential as a drug candidate. Further research is required to fully characterize its properties and potential uses.

InChI:InChI=1/C14H22N2/c15-9-6-13-7-10-16(11-8-13)12-14-4-2-1-3-5-14/h1-5,13H,6-12,15H2

Upstream product

• 194612-36-7 1-benzyl-4-(2-chloroethyl)piperidine 
• 202002-66-2 2-(piperidin-4-yl)acetonitrile 
• 256411-39-9 tert-butyl 4-(cyanomethyl)piperidine-1-carboxylate 
• 197569-11-2 4-(cyanomethylidene)piperidine-1-carboxylic acid tert-butyl ester 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 100-39-0 benzyl bromide 
• 1463-52-1 ethyl 2-(1-benzylpiperidin-4-ylidene)-2-cyanoacetate 
• 55022-82-7 2-(1-benzylpiperidin-4-ylidene)acetonitrile 
• 616897-44-0 2-(1-benzylpiperidin-4-ylidene)malononitrile 
• 86945-27-9 1-benzyl-4-cyanomethylpiperidine-4-carbonitrile 
• 3612-20-2 1-phenylmethyl-4-piperidone 

Downstream Products

• 126848-96-2 Pyridine-2-carboxylic acid [2-(1-benzyl-piperidin-4-yl)-ethyl]-amide 
• 113027-62-6 N-(2-(1-benzylpiperidin-4-yl)ethyl)nicotinamide 
• 126848-98-4 N-(2-(1-benzylpiperidin-4-yl)ethyl)isonicotinamide 
• 126848-93-9 4-Acetyl-N-[2-(1-benzyl-piperidin-4-yl)-ethyl]-benzamide 
• 126849-00-1 N-[2-(1-Benzyl-piperidin-4-yl)-ethyl]-1-oxy-isonicotinamide 
• 126848-94-0 1-benzyl-4-<2-amino>ethyl>piperidine 
• 145232-89-9 1-(3,4-methylenedioxybenzoyl)-3-[2-(1-benzyl-4-piperidyl)ethyl]thiourea 

Relevant articles and documents

Claulansine F-donepezil hybrids as anti-alzheimer’s disease agents with cholinergic, free-radical scavenging, and neuroprotective activities

The multifactorial nature of Alzheimer’s disease (AD) calls for the development of multitarget agents addressing key pathogenic processes. A total of 26 Claulansine F-donepezil hybrids were designed and synthesized as multitarget drugs. Among these compounds, six compounds exhibited excellent acetylcholinesterase (AChE) inhibitory activity (half maximal inhibitory concentration (IC50) 1.63-4.62 μM). Moreover, (E)-3-(8-(tert-Butyl)-3,3-dimethyl-3,11-dihydropyrano[3,2-a]carbazol- 5-yl)-N-((1-(2-chlorobenzyl)piperidin-4-yl)methyl)acrylamide (6bd) exhibited better neuroprotective effects against OGD/R (oxygen-glucose deprivation/reoxygenation) than lead compound Claulansine F. Furthermore, 6bd could cross the blood-brain barrier in vitro. More importantly, compared to edaravone, 6bd had stronger free-radical scavenging activity. Molecular docking studies revealed that 6bd could interact with the catalytic active site of AChE. All of these outstanding in vitro results indicate 6bd as a leading structure worthy of further investigation.

Rational Design and Multibiological Profiling of Novel Donepezil-Trolox Hybrids against Alzheimer's Disease, with Cholinergic, Antioxidant, Neuroprotective, and Cognition Enhancing Properties

A novel series of donepezil-trolox hybrids were designed, synthesized, and evaluated as multifunctional ligands against Alzheimer's disease (AD). Biological assays showed that these derivatives possessed moderate to good inhibitory activities against acetylcholinesterase (AChE) and monoamine oxidase B (MAO-B) as well as remarkable antioxidant effects. The optimal compound 6d exhibited balanced functions with good inhibition against hAChE (IC50 = 0.54 μM) and hMAO-B (IC50 = 4.3 μM), significant antioxidant activity (41.33 μM IC50 by DPPH method, 1.72 and 1.79 trolox equivalent by ABTS and ORAC methods), excellent copper chelation, and Aβ1-42 aggregation inhibition effect. Furthermore, cellular tests indicated that 6d has very low toxicity and is capable of combating oxidative toxin (H2O2, rotenone, and oligomycin-A) induced neurotoxicity. Most importantly, oral administration of 6d demonstrated notable improvements on cognition and spatial memory against scopolamine-induced acute memory deficit as well as d-galactose (d-gal) and AlCl3 induced chronic oxidative stress in a mouse model without acute toxicity and hepatotoxicity. In summary, both in vitro and in vivo results suggested that 6d is a valuable candidate for the development of a safe and effective anti-Alzheimer's drug.

Synthesis and evaluation of multi-target-directed ligands against Alzheimer's disease based on the fusion of donepezil and ebselen

A novel series of compounds obtained by fusing the cholinesterase inhibitor donepezil and the antioxidant ebselen were designed as multi-target-directed ligands against Alzheimer's disease. An in vitro assay showed that some of these molecules did not exhibit highly potent cholinesterase inhibitory activity but did have various other ebselen-related pharmacological effects. Among the molecules, compound 7d, one of the most potent acetylcholinesterase inhibitors (IC50 values of 0.042 μM for Electrophorus electricus acetylcholinesterase and 0.097 μM for human acetylcholinesterase), was found to be a strong butyrylcholinesterase inhibitor (IC50 = 1.586 μM), to possess rapid H2O2 and peroxynitrite scavenging activity and glutathione peroxidase-like activity (ν0 = 123.5 μM min-1), and to be a substrate of mammalian TrxR. A toxicity test in mice showed no acute toxicity at doses of up to 2000 mg/kg. According to an in vitro blood-brain barrier model, 7d is able to penetrate the central nervous system.